A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab

Trial Profile

A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Neratinib (Primary) ; Cetuximab
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Apr 2017 Results evaluating accuracy of a cfDNA assay for HER2 amp to evaluate molecular changes in HER2 copy number, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 01 Mar 2017 According to a Puma Biotechnology media release, data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top